Pilot Evaluation of Paroxetine for Treating Hot Flashes in Men

Loprinzi, Charles L.; Barton, Debra L.; Carpenter, Lisa A.; Sloan, Jeff A.; Novontny, Paul J.; Gettman, Matthew T.; Christensen, Bradley J.
October 2004
Mayo Clinic Proceedings;Oct2004, Vol. 79 Issue 10, p1247
Academic Journal
OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes in men receiving androgen ablation therapy for prostate cancer. PATIENTS AND METHODS: Men with symptomatic androgen ablation therapy-related hot flashes were entered into this clinical trial between August 2001 and October 2003. After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12.5 mg/d, and it was increased to 37.5 mg/d over the ensuing 4 weeks. RESULTS: Of the 24 patients in whom medication was initiated, 18 completed the 5-week study, in these patients, the median frequency of hot flashes decreased from 6.2 per day during the baseline week to 2.5 per day during the last study week. Hot flash scores (frequency × mean severity) during the same period decreased from 10.6 per day to 3.0 per day. Overall, paroxetine was well tolerated by most patients. CONCLUSION: The results from this trial suggest that paroxetine is an effective agent for diminishing hot flashes in men receiving androgen ablation therapy.


Related Articles

  • Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Ploussard, G.; Paule, B.; Salomon, L.; Allory, Y.; Terry, S.; Vordos, D.; Hoznek, A.; Vacherot, F.; Abbou, C.-C.; Culine, S.; De la Taille, A. // Prostate Cancer & Prostatic Diseases;2010, Vol. 13 Issue 1, p97 

    Therapeutic strategy remains unclear with no clear consensus for men with high-risk prostate cancer (PCa) after radical prostatectomy. We aimed to evaluate into a prospective randomized trial the effectiveness and feasibility of adjuvant weekly paclitaxel combined with androgen deprivation...

  • Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial. Zietman, Anthony L.; DeSilvio, Michelle L.; Slater, Jerry D.; Rossi, Carl J.; Miller, Daniel W.; Adams, Judith A.; Shipley, William U. // JAMA: Journal of the American Medical Association;9/14/2005, Vol. 294 Issue 10, p1233 

    Context Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common. Objective To evaluate the hypothesis that increasing the radiation dose delivered to men with clinically localized prostate cancer improves...

  • Length of androgen-deprivation therapy. Elliott, William T. // Clinical Oncology Alert;Aug2009 Supplement, p1 

    The article discusses research aimed at determining the optimal length of androgen-deprivation therapy among men with locally invasive prostate cancer who have received external beam radiation. The study conducted in Europe has revealed that the patients do better when they receive three years...

  • Radiation Dose Escalation as Treatment for Clinically Localized Prostate Cancer: Is More Really Better? DeWeese, Theodore L.; Song, Danny Y. // JAMA: Journal of the American Medical Association;9/14/2005, Vol. 294 Issue 10, p1274 

    Presents an editorial regarding radiation dose escalation as a treatment for clinically localized prostate cancer. Management of clinically localized adenocarcinoma of the prostate; Risk of disease recurrence following therapy; Description of advances in radiotherapy techniques; Reference to a...

  • Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. Kibel, A. S.; Nelson, J. B. // Prostate Cancer & Prostatic Diseases;2007, Vol. 10 Issue 2, p119 

    The management of high-risk prostate cancer following radical prostatectomy remains a treatment dilemma. Multimodality approaches incorporating surgery, radiation therapy and systemic agents offer the hope of improved cure rates; however, most randomized studies to date are either immature or...

  • A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Lee, C. E.; Leslie, W. D.; Czaykowski, P.; J. Gingerich; Geirnaert, M.; Lau, Y. K. J. // Current Oncology;Aug2011, Vol. 18 Issue 4, pe163 

    For advanced and metastatic prostate cancer, androgen deprivation therapy (ADT) is the mainstay of treatment. Awareness of the potential bone-health complications consequent to ADT use is increasing. Many studies have shown that prolonged ADT leads to significant bone loss and increased fracture...

  • Androgen Deprivation Therapy for Localized Prostate Cancer. Kuritzky, Louis // Clinical Cardiology Alert;Sep2008 Clinical Briefs in Primary, Vol. 13 Issue 9, p18 

    This article discusses research being done on the effectiveness of androgen deprivation therapy (ADT) for localized prostate cancer (P-CA). It references a study by G. L. Lu-Yao et al, published in a 2008 issue of the "American Medical Association" (AMA) journal. The researchers examined data on...

  • When "Watchful Waiting" Is OK for Prostate Cancer.  // Tufts University Health & Nutrition Letter;Mar2005, Vol. 23 Issue 1, p3 

    Reports on the potential of "watchful waiting approach" to prostate cancer treatment according to a study conducted by the Erasmus Medical Center in Rotterdam, New York, published in the "Journal of Urology." Reason some men diagnosed with the disease opt for the approach.

  • Drug therapy + standard treatment adds value in prostate cancer? Everitt, Laura // PharmacoEconomics & Outcomes News;6/5/2004, Issue 454, p3 

    Prostate cancer is a prevalent and costly disease in the US, and the most common cancer among men. Non-surgical therapy frequently consists of androgen deprivation therapy (ADT) or radiation treatment combined with hormonal therapy. A study conducted in the US and presented at the 9th Annual...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics